Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495269 | 1.00 | SPHK1 (0.51) | SPHK1ALDH1A1SMN1; SMN2ALOX5KCNH2 | |
| SCHEMBL6484000 | 1.00 | SPHK1 (0.51) | SPHK1ALDH1A1SMN1; SMN2ALOX5KCNH2 | |
| SCHEMBL5689938 | 0.92 | SPHK1 (0.55) | SPHK1ALDH1A1SMN1; SMN2ALOX5KCNH2 | |
| SCHEMBL5689937 | 0.92 | SPHK1 (0.55) | SPHK1ALDH1A1SMN1; SMN2ALOX5KCNH2 | |
| SCHEMBL6836169 | 0.86 | GRIN2B (0.51) | SPHK1ALDH1A1SMN1; SMN2GRIN2B | |
| SCHEMBL5689748 | 0.86 | GRIN2B (0.55) | SPHK1GRIN2B | |
| SCHEMBL5691767 | 0.86 | GRIN2B (0.55) | SPHK1GRIN2B | |
| SCHEMBL5689744 | 0.86 | GRIN2B (0.55) | SPHK1GRIN2B | |
| SCHEMBL6836202 | 0.86 | GRIN2B (0.51) | SPHK1ALDH1A1SMN1; SMN2GRIN2B | |
| SCHEMBL2466298 | 0.83 | TAAR1 (0.53) | GRIN2BJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-25 | — | — | US | claimed |
| CN-1441773-A | Cyclohexylamine derivative as subtype selective NMDA receptor Antagonists | WARNER LAMBERT CO (US) | 2003-09-10 | — | — | CN | claimed |
| EP-1278716-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-01-29 | — | — | EP | claimed |
| WO-2001081295-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| US-6919377-B2 | Cyclohexylamine derivative as subtype selective NMDA receptor antagonists | WARNER LAMBERT COMPANY LLC (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-12-25 | — | — | US | disclosed |
| CN-1441773-A | Cyclohexylamine derivative as subtype selective NMDA receptor Antagonists | WARNER LAMBERT CO (US) | 2003-09-10 | — | — | CN | disclosed |
| EP-1278716-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001081295-A1 | CYCLOHEXYLAMINE DERIVATIVE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236286-A1 | Cyclohexylamine derivative as subtype selective nmda receptor antagonists | GRIN1, GRIN2A, GRIN2B | SPHK1 958/4885ALDH1A1 1840/4885SMN1; SMN2 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.